How can we make clinical trials safer, easier, and less expensive while still ensuring human safety? Are there organizations seriously working on this issue and developing better clinical-trial methods that could be used by medical laboratories worldwide?
Published in Drugs development & discovery, Organisations, People.
Organizations seriously working on exactly this problem
CTTI — Clinical Trials Transformation Initiative is especially close to what you’re describing. It is a public-private partnership co-founded by Duke University and the FDA specifically to develop and promote practices that improve clinical-trial quality, efficiency and patient-centeredness. Its work includes Quality by Design, decentralized trials, safety reporting and simplifying data collection.
ICH — International Council for Harmonisation is even more important if your goal is something that can eventually be used worldwide. ICH creates harmonized drug-development standards across regulatory jurisdictions. Its E6(R3) framework is moving clinical research toward proportionality, risk-based quality management and more flexible trial technologies.
FDA itself has major programs involving decentralized trials, digital technologies, complex innovative designs, master protocols and New Approach Methodologies. This is not merely theoretical research; these concepts are increasingly entering regulatory guidance.
EMA / ACT EU is pursuing a similar transformation in Europe. ACT EU explicitly aims to change how trials are initiated, designed and conducted while promoting high-quality, safe and effective medicines. Europe is also working on decentralized trials and complex methodologies such as master protocols and Bayesian approaches.
TransCelerate BioPharma brings pharmaceutical companies, regulators, CROs, research sites and technology providers together to eliminate redundant processes. Projects include risk-based monitoring, decentralized methods, eConsent, digital data flow and reducing repeated site qualification and training.
Critical Path Institute (C-Path) develops regulatory-science tools such as biomarkers, quantitative models and clinical-trial simulators. In May 2026 it also launched a coalition specifically aimed at accelerating validation and regulatory adoption of human-relevant New Approach Methodologies.
NIH/NCATS is particularly interesting for your idea of making trials safer before humans are exposed. Its Tissue Chip program develops human-cell-based organ systems for predicting drug safety and toxicity, and its “Clinical Trials on a Chip” work is exploring how these technologies can improve trial development and design.
The larger opportunity
There is still something missing: one universally usable, open clinical-trial operating system connecting laboratories, hospitals, ethics committees, regulators and participants internationally.
Conceptually, such a system could combine a standardized protocol generator, automated regulatory documentation, shared control-group data where scientifically justified, real-time safety surveillance, electronic consent, wearable monitoring, standardized CDISC/FHIR data, adaptive statistics, trial simulation, organ-on-chip screening and independent human-safety oversight.
The important principle would be:
Automate administration—not ethics. Reduce unnecessary testing—not necessary safety testing. Use AI to detect risk—not to make unsupervised decisions about human safety.
That could be a genuinely worthwhile research program in its own right. The pieces already exist; the larger challenge is integrating and validating them into a system that regulators around the world can trust.
If this idea is connected to the project on your website, CTTI, C-Path, NCATS and ICH are probably the four organizations I would study first. They are unusually close to the exact problem you’re proposing.